Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

NCT04862234 on ClinicalTrials.gov · last registry update 2025-01-17

Stopped early, having planned 16 participants. The sponsor logged completion for 22 June 2023. Primary outcome, as filed: Percentage of Time in Target Glucose Range (70-140 mg/dL) by CGM.

Status: TERMINATED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Emory University
Sponsor type: Other
Enrollment: 16
Started: 2021-08-06
Primary completion: 2023-06-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Time in Target Glucose Range (70-140 mg/dL) by CGM

Conditions studied

Hyperglycemia Stress

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.